ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Rossari Biotech's board approved unaudited quarterly financial results, granted 4,000 ESOP options, allotted 2,500 equity shares, and restructured overseas subsidiaries via share transfer to Rossari Singapore.
Rossari Biotech re-appointed Ms. Esha Padmanabhan Achan as Independent Director for three years. The Board also approved granting 830,050 stock options under its 2019 ESOP plan.
Rossari Biotech Limited has scheduled a Board Meeting for April 27, 2026, to approve the audited standalone and consolidated financial results for the year ended March 31, 2026. The Board will also consider recommending a final dividend. The trading window remains closed until April 29, 2026.
Rossari Biotech Limited has scheduled a Board Meeting on April 27, 2026, to approve audited financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a final dividend. Consequently, the trading window for designated persons remains closed from April 01, 2026.